Alzheimer’s Getting Worse Despite Treatment: What Should Happen Next?

When memory or daily function continues to decline during treatment, families may wonder whether the disease has relapsed, become resistant or needs a stronger drug immediately. Alzheimer’s disease is not usually managed through the same relapse framework used in cancer. Ongoing progression, unmet expectations, a new illness and treatment-related problems need to be distinguished before deciding what to change.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

Sudden difficulty staying awake, marked confusion, one-sided weakness, altered speech, a seizure or severe headache requires prompt emergency assessment. Do not wait for a scheduled review or begin a long journey to seek an intensified treatment package. A new disturbance of attention or awareness raises concern for delirium or another acute problem. NICE delirium guidance
Patients receiving lecanemab or donanemab should report new headache, visual changes, unsteadiness, confusion or seizures to the treating team. Sudden or severe symptoms warrant emergency assessment. Amyloid-related imaging abnormalities can resemble some stroke presentations, making the antibody name and most recent administration date important information for the emergency team. Leqembi prescribing information, Kisunla prescribing information
The conclusion should explain the most likely cause of the change, which results are still pending, how the current medicines should be administered and what requires earlier contact. If something changes, record its start date and intended outcome. If treatment remains unchanged, the reason should also be clear so that the household does not continue experimenting independently.

Quick answer

Full guide

The first questions concern the speed of change, the abilities affected and possible emergency signs. Even with a confirmed Alzheimer’s diagnosis, a new deterioration may have a treatable contributor. Current therapy cannot guarantee that progression stops, and continued decline does not automatically establish that every previous intervention was useless. NIA treatment overview

Separate changes over hours from changes over months

Sudden difficulty staying awake, marked confusion, one-sided weakness, altered speech, a seizure or severe headache requires prompt emergency assessment. Do not wait for a scheduled review or begin a long journey to seek an intensified treatment package. A new disturbance of attention or awareness raises concern for delirium or another acute problem. NICE delirium guidance

A gradual need for more reminders over several months usually calls for a comprehensive clinical review. Write a short timeline distinguishing longstanding difficulties from new changes. Deterioration beginning after an admission, a new prescription, a change of caregiver or a fall may direct the assessment more effectively than the general statement that the patient is worse.

The timeline should include what the person was able to do before the change. This helps clinicians assess both the immediate problem and the underlying cognitive condition without assuming that they are the same process.

Describe events rather than repeatedly testing memory at home

Record tasks that were previously manageable and now require help. Examples include missed medication, losing the way on a familiar route or needing assistance to dress. Explain whether the difficulty involves forgetting a sequence, limited movement, hearing an instruction or resisting help. Similar-looking problems can have different causes and therefore different responses.

Also describe duration and variation. A problem occurring only at night, an episode lasting minutes with recovery, and a persistent gradual change are not interchangeable histories. Clinical assessment combines the patient’s account, caregiver observations and suitable tools rather than treating one brief screening result as the entire answer. DETeCD-ADRD assessment guideline

Brief, concrete notes are usually more informative than an extensive diary of repeated questions. They can show what has changed without placing the patient under constant examination.

Check what was actually taken

A prescription may not reflect real administration. Doses can be missed, repeated or interrupted, and a brand change may accidentally introduce a duplicate ingredient. Patches and different tablet formulations have distinct instructions. Bring the packs, medication list and actual administration record for a clinician or pharmacist to inspect.

Donepezil can cause problems such as gastrointestinal symptoms, weight loss or fainting. Memantine use also requires attention to kidney function and tolerability. A patient feeling unwell may eat, move or communicate less, which the family first notices as poorer cognition or engagement. Explain the timing of symptoms relative to starting, changing or interrupting treatment. Donepezil information, memantine information

Do not repeatedly stop and restart medicines to test a theory at home. The prescriber should decide how to investigate a suspected effect and how to resume treatment safely after an interruption.

Medicines for other conditions also deserve review

Some sleep, allergy or bladder medicines, and combinations of several products, can contribute to confusion or drowsiness. NICE recommends attention to anticholinergic burden and consideration of alternatives when appropriate. This requires assessment of the specific medicines rather than stopping an entire category indiscriminately. NICE dementia medication recommendations

Include nonprescription drugs, herbal products, supplements and medicines recently supplied by an emergency department. Abruptly stopping a longstanding treatment can itself create problems. Changes should therefore be coordinated with the prescribing team.

If several specialties prescribe independently, ask a clinician or pharmacist responsible for the overall plan to reconcile the list. A record of why each medicine changed and when it will be reviewed helps prevent repeated, conflicting adjustments.

Look for discomfort and changes in the care environment

Pain, constipation, urinary retention, disrupted sleep, dehydration and infection can affect attention and behavior. Someone unable to describe discomfort may resist care, pace, stop eating or become unusually quiet. Examination and the history should guide testing; every patient does not need the same broad investigation package.

An unfamiliar environment, inadequate hearing or visual support, and rushed instructions may also make a previously manageable activity difficult. Assessing these factors does not deny that Alzheimer’s can progress. It avoids overlooking situations that may be improved.

Response to a practical adjustment still needs interpretation over time. A better day after improved sleep does not establish reversal of the underlying disease, just as a difficult day in a noisy clinic does not prove that a new stage has been reached.

Bacteria in a urine test may not explain the deterioration

Older people with cognitive impairment may have asymptomatic bacteriuria. IDSA guidance states that bacteriuria plus acute confusion, without urinary symptoms or systemic signs such as fever or circulatory instability, should prompt assessment of other causes and careful observation rather than automatic antibiotic treatment. Signs of severe infection require timely clinical management; this distinction must not be used to delay care for an acutely unwell person. IDSA asymptomatic bacteriuria guideline

The clinician must interpret the finding in context. Families can report temperature, urinary changes, food intake and alertness, but should not add an antibiotic independently from a laboratory result. Attributing every episode of confusion to a urinary infection can obscure another illness or medication effect.

Equally, an inability to communicate symptoms means the overall assessment is important. The purpose is appropriate evaluation, not a rule that infection can never occur in someone who cannot describe it clearly.

New symptoms during antibody treatment need specific attention

Patients receiving lecanemab or donanemab should report new headache, visual changes, unsteadiness, confusion or seizures to the treating team. Sudden or severe symptoms warrant emergency assessment. Amyloid-related imaging abnormalities can resemble some stroke presentations, making the antibody name and most recent administration date important information for the emergency team. Leqembi prescribing information, Kisunla prescribing information

The team decides whether to pause treatment, obtain further MRI or resume administration based on the findings. Feeling well does not justify skipping scheduled monitoring. A previous normal MRI likewise does not remove the need to assess new symptoms.

Do not switch antibodies or shorten administration intervals independently as a rescue course. The patient’s existing imaging and safety history need continuous review. Moving between providers without those records can make the clinical situation harder to interpret.

An atypically rapid course may require reconsidering the diagnosis

Sometimes the pace of deterioration, additional neurological findings or investigation results prompt a fresh assessment of an earlier Alzheimer’s diagnosis. Rapid cognitive decline has several possible causes. Selected vascular, toxic, metabolic, autoimmune or inflammatory disorders have different management pathways. Research on very rapidly progressive presentations emphasizes identifying relevant causes through the clinical pattern. Study of ultra-rapid progressive dementia

Reassessment may include specialist examination, MRI, EEG or cerebrospinal fluid testing, depending on the question. Not every person needs every investigation. The clinician should explain which uncertainty each test is intended to address.

The existence of a rare treatable disorder is not a reason to begin steroids, immune therapy or anti-infective treatment without supporting evidence. The task is to establish a plausible specific cause, not to try multiple powerful treatments merely because cognition has worsened.

Confirmed gradual progression can still lead to useful adjustments

The team may review eligibility for symptom medicines, address adverse effects or consider an appropriate combination or alternative based on stage. An adjustment should have a defined purpose: better tolerability, relief of a particular symptom or a regimen that can be administered reliably. It should not be presented as a promise that a stronger drug will prevent all further decline.

Assess activity, communication, swallowing, nutrition, sleep and caregiver support at the same time. Some difficulties can improve through changes in care even while the underlying disease progresses. Document the new functional baseline so the next review can assess whether the targeted problem changed. NICE continuing care recommendations

A lack of immediate improvement alone should not determine whether all medicines are stopped. Conversely, continuing indefinitely without reviewing burden or purpose is not a substitute for an assessment.

Worsening behavior requires a defined treatment target

For substantial agitation or dangerous behavior, assess bodily causes and triggers before discussing environmental measures and medication. The goal is relief of distress and risk while maintaining appropriate alertness, movement and eating. Quietness caused by excessive sedation is not automatically a successful outcome.

If the family asks about a newly approved medicine, the clinician must check the relevant indication, contraindications, interactions and local availability. A U.S. announcement cannot stand in for the applicable prescribing basis in China. Severe agitation should not lead to improvised combinations of sedatives or sleep medicines at home.

Obtain a clear route for urgent help and know when an institution capable of assessing acute illness is needed. Sudden behavioral changes deserve particular attention to an underlying medical problem.

Establish stability before traveling to China for another opinion

A second opinion may clarify a gradual decline when the diagnosis or treatment plan remains uncertain. Send original imaging, pathology-related investigations, previous assessments and the actual medication history in advance. Describe present function and the help needed. The receiving hospital can then advise which specialty should assess first and whether further records or an inpatient evaluation may be necessary.

Unexplained acute confusion, fever or new neurological symptoms should be addressed locally before a long journey. An existing appointment in China does not remove the need to manage the immediate situation. Travel can add complexity to assessment and care.

The second opinion should also identify who will carry out the subsequent plan. This is particularly important for treatment requiring continuing surveillance. Several clinicians adjusting the regimen independently without shared information may create additional uncertainty.

Leave the review with a specific next step

The conclusion should explain the most likely cause of the change, which results are still pending, how the current medicines should be administered and what requires earlier contact. If something changes, record its start date and intended outcome. If treatment remains unchanged, the reason should also be clear so that the household does not continue experimenting independently.

Identify the main contact and where additional caregiving help can be obtained. Repeated falls, swallowing difficulty or intensive night-time supervision may mean that the support arrangement needs revision. The extra work created by deterioration deserves direct discussion.

Finding another drug is only one possible response. A review that produces an executable medical and care plan is what makes the next step useful to the patient and family.